Table 1.
SNP | Gene | Name | P-Value |
---|---|---|---|
rs10871454 | VKORC1 | Vitamin K1 2,3-epoxide reductase subunit 1 | 9.31E-10 |
rs4086116 | CYP2C9 | cytochrome P450, family 2, subfamily C | 7.54E-05 |
rs4917639 | CYP2C9 | cytochrome P450, family 2, subfamily C | 9.47E-05 |
rs9332169 | CYP2C9 | cytochrome P450, family 2, subfamily C | 2.33E-04 |
rs9332214 | CYP2C9 | cytochrome P450, family 2, subfamily C | 2.33E-04 |
rs10509680 | CYP2C9 | cytochrome P450, family 2, subfamily C | 2.33E-04 |
rs12445568 | HSD3B7 | 3-beta-HSD VII | 3.84E-04 |
rs12357515 | EXOC6 | Exocyst complex component Sec15A | 3.86E-04 |
rs11187215 | EXOC6 | Exocyst complex component Sec15A | 3.87E-04 |
rs7294 | VKORC1 | Vitamin K1 2,3-epoxide reductase subunit 1 | 4.15E-04 |
Top 10 of 3,856 SNPs fitting a univariate linear regression model of warfarin dose for 181 patients. Bold SNPs are significant after multiple hypothesis testing. Only rs10871454 (a SNP in 100% LD with VKORC1) was significant after correcting for multiple hypothesis testing.